Whole-organ decellularization removes the cells of a cadaveric liver by detergent perfusion through its own vascular tree while preserving the extracellular matrix and the organ's hierarchical vascular network, which can then be used both as a perfusion route and as a cell-delivery channel for recellularization. Baptista et al. (Hepatology 2011) distilled what still separates this proof of concept from a functional, transplantable graft into five unresolved issues: incomplete endothelialization of the vascular tree down to the capillaries; the unknown mechanism by which infused cells transit from vascular channels into the parenchymal space; clotting-limited in vivo blood perfusion; the inability to seed a human-sized scaffold with the on the order of 10×101010 \times 10^{10} parenchymal cells it requires; and undefined decellularization parameters balancing matrix preservation against complete cell removal. Major partial progress has been reported - 15-day heterotopic blood perfusion of re-endothelialized porcine scaffolds, a 28-day auxiliary human-scale graft, and approximately 81% vascular coverage in peptide-engineered scaffolds - but no closure of any component: complete endothelialization including sinusoids, long-term non-thrombogenic orthotopic perfusion, and clinical-scale functional recellularization all remain open, as do the mechanistic and protocol sub-questions.

Background

Liver transplantation is the only curative treatment for end-stage liver disease and is chronically limited by donor-organ shortage. One tissue-engineering strategy for closing this gap is whole-organ decellularization: a cadaveric liver is perfused through its own vascular tree with detergents that remove all cells while leaving the extracellular matrix (ECM - the collagen-, laminin-, and glycosaminoglycan-rich network that provides structural support and biochemical cues to cells) together with the organ's hierarchical vascular network, from large inflow and outflow vessels down to capillaries roughly 10-20 micrometers in diameter. The resulting acellular scaffold can in principle be recellularized with recipient-derived cells and anastomosed to the recipient's circulation, producing a transplantable graft. Because cells in any engineered tissue die when more than a few hundred micrometers from a nutrient source, this perfusable, native-scale vascular network is the decisive asset of the decellularization route: synthetic or micropatterned scaffolds cannot yet reproduce its multiscale branching geometry.

Uygun et al. (Nature Medicine 2010) demonstrated the first transplantable recellularized liver graft at rat scale, with short-term function. Baptista et al. (Hepatology 2011), the source of the open question, then showed that perfusion decellularization (distilled water followed by 1% Triton X-100 with 0.1% ammonium hydroxide) preserves a patent, connected vascular tree in mouse, rat, ferret, and pig livers; that the vascular route can deliver endothelial cells (the cells that form the inner lining of blood vessels), which deposit in zone-dependent patterns depending on whether infusion is via the portal vein or the vena cava and measurably reduce platelet adhesion; and that co-perfusion of human fetal liver cells (hFLCs) with human umbilical vein endothelial cells (HUVECs, a standard endothelial cell source) into decellularized ferret livers generates liver-like tissue expressing albumin, alpha-fetoprotein, CYP (cytochrome P450) detoxification enzymes, and the biliary marker cytokeratin 19. Two observations defined the limits of the proof of concept. First, a fluorescently labeled 250 kDa dextran (an inert polysaccharide tracer molecule) perfused through the vascular tree leaked into the parenchymal space after 5-10 minutes, indicating that the capillary-scale walls of the decellularized scaffold are not fully intact; this same leakage is presumably how infused parenchymal cells reach the parenchymal space, but whether transit is passive leakage or active cell penetration was not determined. Second, unseeded scaffolds anastomosed and transplanted into rats remained patent only up to about 60 minutes under heparinization before clotting - the bare ECM lumen is highly thrombogenic (prone to triggering blood clotting). The authors further note that a human-sized scaffold would require on the order of 10×101010 \times 10^{10} parenchymal cells for clinical-scale recellularization - roughly the hepatocyte content of an adult human liver - a number no existing seeding method can deliver, and that detergent type, concentration, and perfusion volumes and rates must be optimized to preserve ECM composition while guaranteeing complete cell removal across organ sizes and species. For orientation on what followed: re-endothelialization means re-establishing a complete endothelial lining on those luminal surfaces; the liver's own capillaries are called sinusoids, lined by specialized liver sinusoidal endothelial cells; heterotopic or auxiliary transplantation places a graft at an ectopic site or as an additional liver without removing the native one, whereas orthotopic transplantation replaces the native liver in its anatomic position, a far more demanding test of blood compatibility and function.

Problem Statement

Carry the whole-organ decellularization route for the liver from proof of concept to a functional, transplantable graft. Baptista et al. (2011) formulate this as five unresolved issues that share one objective - a bioengineered liver that, after implantation and vascular anastomosis (surgical connection of the graft's vessels to the recipient's circulation), sustains blood perfusion and performs liver function at clinically meaningful scale - and they are stated here as the components of that single problem:

(1) Complete endothelialization: achieve stable, functionally confluent endothelial coverage of the entire preserved vascular tree of a decellularized liver scaffold, including the sinusoid-scale capillaries (the liver's specialized capillaries) and not only the macrovessels, with coverage demonstrated quantitatively across the whole organ. (2) Cell-transit mechanism: determine, by targeted experiments, how infused parenchymal and progenitor cells pass from the vascular channels into the parenchymal space - specifically whether transit is driven by leakage through focal extracellular-matrix discontinuities in the decellularized capillary walls (suggested by dextran extravasation after 5-10 minutes of perfusion), by active cell-mediated penetration, or by both. (3) Non-thrombogenic in vivo perfusion: develop and validate strategies (the complete endothelialization of component (1), antithrombotic surface modification, or equivalent) that maintain blood perfusion through the graft after implantation for transplant-relevant durations without clot formation and without prohibitive systemic anticoagulation. (4) Clinical-scale recellularization: deliver and maintain on the order of 10×101010 \times 10^{10} functional parenchymal cells (hepatocyte-equivalents from expandable sources - primary cells, pluripotent-stem-cell derivatives, or liver organoids) uniformly throughout a human-sized scaffold while preserving hepatic phenotype and organ-level functions such as albumin and urea synthesis and ammonia detoxification. (5) Decellularization protocol definition: define and validate decellularization parameters - detergent type and concentration, perfusion volumes and rates - that maximize extracellular-matrix (ECM) preservation while guaranteeing complete cell removal, with reproducible scaffold biochemical properties across organ sizes and species.

The components are jointly necessary and interdependent: (1) and (3) together determine whether the graft can be blood-perfused at all, since any uncovered luminal patch is thrombogenic; (4) determines whether a perfused graft could function at clinical scale; (2) and (5) are the enabling mechanistic and process sub-questions the source identifies as requiring targeted further work on that path - cell delivery through the vascular tree depends on the transit mechanism of (2), and every downstream step depends on the scaffold quality fixed by (5).

All five components are mandatory: a research answer must address each of them, so a result confined to a subset - however complete - leaves the composite problem open, and each component is closed only by satisfying the requirement stated for it above.

References

  1. Baptista PM, Siddiqui MM, Lozier G, Rodriguez SR, Atala A, Soker S. The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology 2011;53(2):604-617. DOI: 10.1002/hep.24067. https://doi.org/10.1002/hep.24067.
  2. Uygun BE, Soto-Gutierrez A, Yagi H, Izamis ML, Guzzardi MA, Shulman C, Milwid J, Kobayashi N, Tilles A, Berthiaume F, Hertl M, Nahmias Y, Yarmush ML, Uygun K. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nature Medicine 2010;16:814-820. DOI: 10.1038/nm.2170. https://doi.org/10.1038/nm.2170
  3. Devalliere J, Chen Y, Dooley K, Yarmush ML, Uygun BE. Improving functional re-endothelialization of acellular liver scaffold using REDV cell-binding domain. Acta Biomaterialia 2018;78:151-164. DOI: 10.1016/j.actbio.2018.07.046. https://doi.org/10.1016/j.actbio.2018.07.046
  4. Watanabe M, Yano K, Okawa K, Yamashita T, Tajima K, Sawada K, Yagi H, Kitagawa Y, Tanishita K, Sudo R. Construction of sinusoid-scale microvessels in perfusion culture of a decellularized liver. Acta Biomaterialia 2019;95:307-318. DOI: 10.1016/j.actbio.2018.12.042. https://doi.org/10.1016/j.actbio.2018.12.042
  5. Shaheen MF, Joo DJ, Ross JJ, Anderson BD, Chen HS, Huebert RC, Li Y, Amiot B, Young A, Zlochiver V, Nelson E, Mounajjed T, Dietz AB, Michalak G, Steiner BG, Davidow DS, Paradise CR, van Wijnen AJ, Shah VH, Liu M, Nyberg SL. Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs. Nature Biomedical Engineering 2020;4:437-445. DOI: 10.1038/s41551-019-0460-x. https://doi.org/10.1038/s41551-019-0460-x
  6. Anderson BD, Nelson ED, Joo D, Amiot BP, Katane AA, Mendenhall A, Steiner BG, Stumbras AR, Nelson VL, Palumbo RN, Gilbert TW, Davidow DS, Ross JJ, Nyberg SL. Functional characterization of a bioengineered liver after heterotopic implantation in pigs. Communications Biology 2021;4:1157. DOI: 10.1038/s42003-021-02665-2. https://doi.org/10.1038/s42003-021-02665-2
  7. Higashi H, Yagi H, Kuroda K, Tajima K, Kojima H, Nishi K, Morisaku T, Hirukawa K, Fukuda K, Matsubara K, Kitago M, Shinoda M, Obara H, Adachi S, Nishimura K, Natsume T, Tomi M, Soto-Gutierrez A, Kitagawa Y. Transplantation of bioengineered liver capable of extended function in a preclinical liver failure model. American Journal of Transplantation 2022;22:731-744. DOI: 10.1111/ajt.16928. https://doi.org/10.1111/ajt.16928
  8. Krüger M, Samsom RA, Oosterhoff LA, van Wolferen ME, Kooistra HS, Geijsen N, Penning LC, Kock LM, Sainz-Arnal P, Baptista PM, Spee B. High level of polarized engraftment of porcine intrahepatic cholangiocyte organoids in decellularized liver scaffolds. Journal of Cellular and Molecular Medicine 2022;26:4949-4958. DOI: 10.1111/jcmm.17510. https://doi.org/10.1111/jcmm.17510
  9. Li K, Tharwat M, Larson EL, Felgendreff P, Hosseiniasl SM, Rmilah AA, Safwat K, Ross JJ, Nyberg SL. Re-Endothelialization of Decellularized Liver Scaffolds: A Step for Bioengineered Liver Transplantation. Frontiers in Bioengineering and Biotechnology 2022;10:833163. DOI: 10.3389/fbioe.2022.833163. https://doi.org/10.3389/fbioe.2022.833163
  10. Toprakhisar B, Verfaillie CM, Kumar M. Advances in Recellularization of Decellularized Liver Grafts with Different Liver (Stem) Cells: Towards Clinical Applications. Cells 2023;12(2):301. DOI: 10.3390/cells12020301. https://doi.org/10.3390/cells12020301
  11. Gupta S, Sharma A, Petrovski G, Verma RS. Vascular reconstruction of the decellularized biomatrix for whole-organ engineering—a critical perspective and future strategies. Frontiers in Bioengineering and Biotechnology 2023;11:1221159. DOI: 10.3389/fbioe.2023.1221159. https://doi.org/10.3389/fbioe.2023.1221159
  12. Afzal Z, Huguet EL. Bioengineering liver tissue by repopulation of decellularised scaffolds. World Journal of Hepatology 2023;15(2):151-179. DOI: 10.4254/wjh.v15.i2.151. https://doi.org/10.4254/wjh.v15.i2.151
  13. Guo B, Zhou Q, Chen J, Xin J, Jiang L, Yang H, Shi D, Ren K, Yang G, Li J, Zhou X, Li P, Luo J, He L, Hassan HM, Liang X, Yao H, Ma S, Li B, Geng L, Wang C, Jiang J, Li J. Orthotopic Transplantation of Functional Bioengineered Livers in Rats. ACS Biomaterials Science & Engineering 2023;9:1940-1951. DOI: 10.1021/acsbiomaterials.2c01213. https://doi.org/10.1021/acsbiomaterials.2c01213
  14. Hussein KH, Ahmadzada B, Correa JC, Sultan A, Wilken S, Amiot B, Nyberg SL. Liver tissue engineering using decellularized scaffolds: Current progress, challenges, and opportunities. Bioactive Materials 2024;40:280-305. DOI: 10.1016/j.bioactmat.2024.06.001. https://doi.org/10.1016/j.bioactmat.2024.06.001
  15. Stoian A, Adil A, Biniazan F, Haykal S. Two Decades of Advances and Limitations in Organ Recellularization. Current Issues in Molecular Biology 2024;46(8):9179-9214. DOI: 10.3390/cimb46080543. https://doi.org/10.3390/cimb46080543
  16. Yadav CJ, Yadav U, Afrin S, Lee JY, Kamel J, Park KM. Heparin Immobilization Enhances Hemocompatibility, Re-Endothelization, and Angiogenesis of Decellularized Liver Scaffolds. International Journal of Molecular Sciences 2024;25(22):12132. DOI: 10.3390/ijms252212132. https://doi.org/10.3390/ijms252212132
  17. Horie H, Oshima Y, Fukumitsu K, Iwaki K, Munekage F, Makino K, Wakama S, Ito T, Tomofuji K, Ogiso S, Uebayashi EY, Ishii T, Ishihara K, Hatano E. Antithrombotic Revascularization Strategy of Bioengineered Liver Using a Biomimetic Polymer. Tissue Engineering Part A 2025;31:433-441. DOI: 10.1089/ten.tea.2024.0131. https://doi.org/10.1089/ten.tea.2024.0131
  18. Yadav U, Yadav CJ, Afrin S, Lee JY, Kamel J, Park KM. Sphingosine-1-Phosphate (S1P) in Whole Liver Recellularization Improves Endothelization of Acellular Liver Scaffold. ACS Biomaterials Science & Engineering 2025;11:4345-4356. DOI: 10.1021/acsbiomaterials.5c00411. https://doi.org/10.1021/acsbiomaterials.5c00411
  19. Morawski M, Krasnodębski M, Rochoń J, Kubiszewski H, Marzęcki M, Topyła D, Murat K, Staszewski M, Szczytko J, Maleszewski M, Grąt M. Decellularized Liver Matrices for Expanding the Donor Pool—An Evaluation of Existing Protocols and Future Trends. Biomolecules 2025;15(1):98. DOI: 10.3390/biom15010098. https://doi.org/10.3390/biom15010098
  20. van Hengel EVA, van der Laan LJW, de Jonge J, Verstegen MMA. Towards Safety and Regulation Criteria for Clinical Applications of Decellularized Organ-Derived Matrices. Bioengineering 2025;12(2):136. DOI: 10.3390/bioengineering12020136. https://doi.org/10.3390/bioengineering12020136
  21. Yadav U, Yadav CJ, Afrin S, Lee JY, Kamel J, Park KM. LXW7 Peptide Modification of Acellular Liver Scaffolds Improves Endothelialization and Hemocompatibility in Bioengineered Liver. Journal of Functional Biomaterials 2026;17(3):122. DOI: 10.3390/jfb17030122. https://doi.org/10.3390/jfb17030122
  22. Le TH, Hyun K, Tabatabaei Rezaei N, Nguyen CT, Hlabano SJ, Le VP, Kim K, Koo KI. A Systematic Review on Artificial Liver for Implantation. Journal of Functional Biomaterials 2026;17(2):73. DOI: 10.3390/jfb17020073. https://doi.org/10.3390/jfb17020073
  23. Sonoda K, Yagi H, Nagata S, Tsuchida T, Nishi K, Morisaku T, Ohtomo M, Adachi S, Okamoto S, Kamishibahara Y, Kuse Y, Taniguchi H, Kitagawa Y. Generation of bioengineered liver grafts densely recellularized using human liver organoids. Cell Transplantation 2026;35:09636897261474318. DOI: 10.1177/09636897261474318. https://doi.org/10.1177/09636897261474318